NCT01730404CompletedPhase 2
A Randomised, Double-blind, Double-dummy, Placebo and Active-controlled, Three-way Crossover Study to Evaluate the Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI (1200 µg Daily) in Subjects With COPD
Chiesi Farmaceutici S.p.A.5 sites in 2 countries55 target enrollmentStarted: October 2012Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Enrollment
- 55
- Locations
- 5
- Primary Endpoint
- Adverse events, adverse drug reactions, serious adverse.
Study Overview
Brief Summary
Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF 6001 (a PDE4 inhibitor) after 28-days of daily inhaled dosing.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Written informed consent obtained prior to any study-related procedures.
- •Male or female aged between 40 and 70 years inclusive.
- •Current or past smoker of at least 10 pack/years
- •BMI in the range of 18-35 Kg/m2
- •GOLD Stage 2 and 3 COPD subjects
- •A history of chronic bronchitis defined as chronic cough and sputum production
- •At screening, subjects must be able to produce an adequate induced sputum sample
- •Female subjects: post-menopausal women having at least 12 months of natural (spontaneous) amenorrhea, or women of childbearing potential using two acceptable methods of contraception for the duration of the study and for the following three months
- •Exclusion criteria:
- •Female subjects: pregnant or lactating women
- •Past or current history of asthma
- •History of clinically significant hypotensive episodes
- •History or symptoms of significant cardiovascular disease
- •History or symptoms of significant neurological disease
- •Unstable concurrent disease
- •An abnormal and clinically significant 12-lead ECG
- •Clinically relevant abnormal laboratory values
- •Use of oral or systemic corticosteroids oral and/or nebulised Beta2 agonists and/or antibiotics within 6 weeks preceding the screening visit
- •Moderate or severe hepatic impairment (Child-Pugh B or C)
- •Intolerance/hypersensitivity or any contraindication to treatment with roflumilast, tiotropium bromide or salbutamol or any of the excipients contained in the formulations used in the study
- •Chronic use of any other medication for treatment of lung disease like xanthines, antileukotrienes, systemic and inhaled corticosteroids, long acting beta2- agonists, roflumilast (other than the study drug) and cromoglycates
- •Long term (at least 12 hours daily) use of oxygen therapy for chronic hypoxemia.
- •Having received an investigational medicinal drug within 30 days prior to study entry
- •Blood draws of 250 mL or more within 45 days prior to enrolment into the study.
- •Known respiratory disorders other than COPD.
- •History of alcohol dependency, or substance abuse
- •Inability to comply with the study Protocol for any other reason.
Exclusion Criteria
- Not provided
Arms & Interventions
CHF6001
Experimental
CHF6001 DPI (Dry Powder Inhaler) once daily
Intervention: CHF6001 DPI (Drug)
Roflumilast
Active Comparator
Roflumilast, tablet, once daily
Intervention: Roflumilast (Drug)
placebo
Placebo Comparator
Placebo
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Adverse events, adverse drug reactions, serious adverse.
Time Frame: After 28 days of treatment
The number and percentage of subjects experiencing AEs, ADRs, serious AEs and AEs leading to study withdrawal.
Vital signs
Time Frame: After 28 days of treatment
12-lead ECG parameters
Time Frame: After 28 days of treatment
Secondary Outcomes
- Pharmacokinetics of CHF 6001 and its metabolites(After 28 days of treatment)
- Induction of sputum(After 28 days of treatment)
- Baseline Dyspnea Index and Transition Dyspnea Index Questionnaire(After 28 days of treatment)
- Lung function measurements(After 28 days of treatment)
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Completed
Phase 2
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPostural Orthostatic Tachycardia SyndromeNCT05633407argenx53
Terminated
Phase 2
Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseCharcot-Marie-Tooth DiseaseNCT03124459Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA63
Terminated
Phase 1
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)Celiac DiseaseNCT05574010Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA128
Active, not recruiting
Phase 2
Study of SPG302 in Adults With SchizophreniaSchizophreniaNCT06442462Spinogenix32
Completed
Phase 2
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT01742208Lexicon Pharmaceuticals36